Last Updated : February 21, 2025
Details
FilesGeneric Name:
clindamycin plus benzoyl peroxide and adapalene
Project Status:
Complete
Therapeutic Area:
acne vulgaris
Manufacturer:
Bausch Health, Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cabtreo
Project Line:
Reimbursement Review
Project Number:
SR0794-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 29, 2024 |
|---|---|
| Call for patient/clinician input closed | March 25, 2024 |
| Clarification: - Patient input submission received from Acne and Rosacea Society of Canada (ARSC) and Canadian Skin Patient Alliance (CSPA) | |
| Submission received | March 08, 2024 |
| Submission accepted | March 26, 2024 |
| Clarification: - Submission was not accepted for review on 25 Mar 2024 | |
| Review initiated | March 27, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | June 20, 2024 |
| Deadline for sponsors comments | July 03, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | August 16, 2024 |
| Expert committee meeting (initial) | August 28, 2024 |
| Draft recommendation issued to sponsor | September 11, 2024 |
| Draft recommendation posted for stakeholder feedback | September 19, 2024 |
| End of feedback period | October 04, 2024 |
| Final recommendation issued to sponsor and drug plans | October 18, 2024 |
| Final recommendation posted | November 05, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | November 01, 2024 |
| CADTH review report(s) posted | February 21, 2025 |
Files
Last Updated : February 21, 2025